Gain Therapeutics Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Gain Therapeutics Inc in the second quarter 2026?
Gain Therapeutics Inc recorded a cumulative net loss of $-20 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -161.58%.

Within the Major Pharmaceutical Preparations industry 297 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3588 to 3767.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	205.52 %	142.35 %	152.94 %	-33.67 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-20	-21	-20	-19	-19
Return On Equity (TTM)	-161.58 %	-201.43 %	-237.54 %	-341.33 %	-289.11 %
GANX's Total Ranking	# 3767	# 3588	# 3289	# 3210	# 3332
Equity (TTM) in Millions	11	14	19	6	4
Seq. Equity Change	-19.38 %	-24.55 %	214.15 %	59.89 %	-36.05 %
Seq. Net Income Change	-	-	-	-	-

Back to GANX Management Effectiveness >> GANX's 5 Years Annual ROE >> Compare GANX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 298
Sector	# 635
Overall	# 3767

Return On Equity Statistics
High	Average	Low
-35.12 %	-166.79 %	-341.33 %
(Dec 31 2021)		(Sep 30 2025)

News about Gain Therapeutics inc Return on Equity ROE

Gain Therapeutics Appoints Gene Mack as CEO Amid Phase 1b Clinical Trial for Parkinsons Treatment and Financial Challenges

Gain Therapeutics Inc. an innovative biotechnology firm focused on developing therapies for neurodegenerative diseases, has announced the appointment of Gene Mack as its new Chief Executive Officer (CEO) and Director. Mack has been with the company since April 2024, serving as Chief Financial Officer (CFO) before stepping in as the interim CEO in June 2024. His extensive experience in financial management and leadership positions him well to guide Gain Therapeutics through its current trials and tribulations.Mack s leadership comes at a critical time for Gain Therapeutics, which recorded a cumulative net loss of $21 million for the 12 months ending in the third quarter of 2024. This substantial loss has resulted in a staggering negative return on equity (ROE) of -203.91%. Within the Major Pharmaceutical Preparations industry, which comprises 273 companies, Gain Therapeutics financial performance lags behind many of its peers, some of which have reported higher ROE figures and overall financial stability. Despite the difficulties, the company s ROE ranking has improved from 3555 in the second quarter of 2024 to 2972 in the most recent quarter, indicating a potential upward trend in operational performance.

Gain Therapeutics Fortifies Management Team with Appointment of Dr. Jonas Hannestad as Chief Medical Officer

Gain Therapeutics Bolsters Management Team with Appointment of Chief Medical Officer, Dr. Jonas Hannestad
BETHESDA, Md., April 01, 2024 - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company specializing in the development of next-generation allosteric small molecule therapies, is pleased to announce the appointment of Dr. Jonas Hannestad, M.D., Ph.D., as its Chief Medical Officer. Dr. Hannestad assumed his new role on March 25, 2024, and his addition to the team is expected to provide valuable expertise and leadership as Gain Therapeutics continues its pioneering work in the field of biotechnology.
Recently, Gain Therapeutics Inc shares have experienced a slight decline and are currently trading on the NASDAQ at 2.7% below their 52-week average. Despite this, the company remains focused on its mission to revolutionize the therapeutic landscape through the development of innovative treatments.

GANX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	19	7	13	19	35
Y / Y Equity Change	152.94 %	-41.65 %	-33.38 %	-45.78 %	-
Net Income in Millions	-20	-20	-22	-18	-14
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-108.6 %	-278.1 %	-177.03 %	-93.17 %	-39.9 %

Back to GANX Management Effectiveness >> GANX's 5 Years Annual ROE >> Compare GANX ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GANX's' Return on Equity at Yahoo Finance
GANX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GANX's Competitors
Subscribers only: Roe for Gain Therapeutics Inc's Suppliers
Subscribers only: Return On Equity for GANX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T17:52:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.